title: Metabolic, electrolytes disorders and tromboembolic risk in malignant glioma patients.
abstract: In malignant gliomas, the management of symptoms and minimization of side effects assume major importance. Corticosteroids provide transient relief from neurological symptoms. However, treatment with steroids is also commonly associated with considerable side-effects including: hyperglycemia, osteoporosis, myopathy, lymphopenia and others. Sometimes, antiepileptic drugs may contribute to clinical decline of neuro-oncological patients in stable disease not only by neuropsychological impairment but also by metabolic interations. Several studies have demonstrated a high frequency of hyponatremia among patients treated with carbamazepine and particularly with oxacarbamazepine. Venous thromboembolism is a common complication in patients with cancer and it is particularly high in malignant gliomas, occurring in approximately 20-30% of such patients. Prophylactic treatment in patients with glioblastoma is a key topic. The role of prophylaxis has not yet been established with certainty. Overall the data show a clear reduction of venous thromboembolic events in patients treated with intermittent pneumatic compression (IPC). The addition of enoxaparin dose of 6.000 UI, starting in the perioperative period, induces an increase of major bleeding events. In the absence of availability of IPC, the use of enoxaparin 4.000 UI in addition to graduated compression stockings, reduces thromboembolic events without major bleeding events.
authors: Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milan, Italy. silvani.a@istituto-besta.it
authors: A
authors: A
authors: Silvani
authors: P
authors: P
authors: Gaviani
authors: E
authors: E
authors: Lamperti
authors: A
authors: A
authors: Botturi
authors: D
authors: D
authors: Ferrari
authors: G
authors: G
authors: Simonetti
authors: L
authors: L
authors: Fariselli
authors: A
authors: A
authors: Salmaggi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy; D005910:Glioma / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007010:Hyponatremia / Q000150:complications* / Q000517:prevention & control; D008659:Metabolic Diseases / Q000150:complications* / Q000517:prevention & control; D013923:Thromboembolism / Q000150:complications* / Q000517:prevention & control; D014882:Water-Electrolyte Balance
chemical_list: D000305:Adrenal Cortex Hormones